David A. Siegel Acumen Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 423,600 shares of ABOS stock, worth $754,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
423,600
Previous 426,300
0.63%
Holding current value
$754,008
Previous $494,000
52.63%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ABOS
# of Institutions
72Shares Held
36.2MCall Options Held
11.6KPut Options Held
0-
Ra Capital Management, L.P. Boston, MA14.9MShares$26.6 Million0.46% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$6.08 Million2.33% of portfolio
-
Franklin Resources Inc San Mateo, CA2.31MShares$4.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$3.84 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$2.94 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $72.1M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...